IAVI 006

Phase:
I/II
Status:
Completed
Strategies:
DNA; Viral Vector - Pox
Candidates:
DNA.HIVA ; MVA.HIVA
Countries:
United Kingdom
Volunteers:
120
Partners:
John Warin Ward, The Churchill, Headington, Oxford, UK; St. Mary's Hospital, London, UK; Medical Research Council (MRC), Oxford, UK.

Study Summary:
The objectives of this study are to evaluate and compare the safety and immunogenicity of two doses of candidate HIV-1 clade A DNA vaccine versus a placebo (delivered by intramuscular injection) followed by a candidate HIV-1 clade A MVA vaccine or placebo.